These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 24571452

  • 21. ABT-263 induces G1/G0-phase arrest, apoptosis and autophagy in human esophageal cancer cells in vitro.
    Lin QH, Que FC, Gu CP, Zhong DS, Zhou D, Kong Y, Yu L, Liu SW.
    Acta Pharmacol Sin; 2017 Dec; 38(12):1632-1641. PubMed ID: 28713162
    [Abstract] [Full Text] [Related]

  • 22. ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer.
    Chen Q, Song S, Wei S, Liu B, Honjo S, Scott A, Jin J, Ma L, Zhu H, Skinner HD, Johnson RL, Ajani JA.
    Oncotarget; 2015 Sep 22; 6(28):25883-96. PubMed ID: 26317542
    [Abstract] [Full Text] [Related]

  • 23. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
    Yun SM, Jung KH, Lee H, Son MK, Seo JH, Yan HH, Park BH, Hong S, Hong SS.
    Cancer Lett; 2013 May 01; 331(2):250-61. PubMed ID: 23340175
    [Abstract] [Full Text] [Related]

  • 24. Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma In Vivo.
    Tsai JJ, Hsu FT, Pan PJ, Chen CW, Kuo YC.
    Anticancer Res; 2018 Apr 01; 38(4):2119-2125. PubMed ID: 29599330
    [Abstract] [Full Text] [Related]

  • 25. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT, Liu YC, Chiang IT, Liu RS, Wang HE, Lin WJ, Hwang JJ.
    Int J Oncol; 2014 Jul 01; 45(1):177-88. PubMed ID: 24807012
    [Abstract] [Full Text] [Related]

  • 26. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
    Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caraballo M, Robbins R, Wagner BL, Rideout WM, Jakubik CT, Ham J, Edelman EJ, Ebi H, Yeo AT, Hata AN, Song Y, Patel NU, March RJ, Tam AT, Milano RJ, Boisvert JL, Hicks MA, Elmiligy S, Malstrom SE, Rivera MN, Harada H, Windle BE, Ramaswamy S, Benes CH, Jacks T, Engelman JA.
    Proc Natl Acad Sci U S A; 2015 Mar 17; 112(11):E1288-96. PubMed ID: 25737542
    [Abstract] [Full Text] [Related]

  • 27. Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts.
    Eicher C, Dewerth A, Thomale J, Ellerkamp V, Hildenbrand S, Warmann SW, Fuchs J, Armeanu-Ebinger S.
    Br J Cancer; 2013 Feb 05; 108(2):334-41. PubMed ID: 23257893
    [Abstract] [Full Text] [Related]

  • 28. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.
    Wang G, Zhan Y, Wang H, Li W.
    Cancer Chemother Pharmacol; 2012 Mar 05; 69(3):799-805. PubMed ID: 22037880
    [Abstract] [Full Text] [Related]

  • 29. Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
    Liu Q, Mier JW, Panka DJ.
    Mol Cancer; 2011 Sep 19; 10():115. PubMed ID: 21929745
    [Abstract] [Full Text] [Related]

  • 30. Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma.
    Gillissen B, Richter A, Richter A, Preissner R, Schulze-Osthoff K, Essmann F, Daniel PT.
    J Biol Chem; 2017 Apr 21; 292(16):6478-6492. PubMed ID: 28154184
    [Abstract] [Full Text] [Related]

  • 31. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Hayashi N.
    Hepatology; 2010 Oct 21; 52(4):1310-21. PubMed ID: 20799354
    [Abstract] [Full Text] [Related]

  • 32. Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma.
    Giovannini C, Baglioni M, Baron Toaldo M, Ventrucci C, D'Adamo S, Cipone M, Chieco P, Gramantieri L, Bolondi L.
    Oncotarget; 2013 Oct 21; 4(10):1618-31. PubMed ID: 24113128
    [Abstract] [Full Text] [Related]

  • 33. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-XL inhibitor ABT-263 in KRAS-mutant colorectal cancers.
    Oh Y, Jung HR, Min S, Kang J, Jang D, Shin S, Kim J, Lee SE, Sung CO, Lee WS, Lee C, Jeong EM, Cho SY.
    Cancer Lett; 2021 Jan 28; 497():123-136. PubMed ID: 33068701
    [Abstract] [Full Text] [Related]

  • 34. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S, Dai Y, Harada H, Dent P, Grant S.
    Cancer Res; 2007 Jan 15; 67(2):782-91. PubMed ID: 17234790
    [Abstract] [Full Text] [Related]

  • 35. Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways.
    Zhang YW, Jiang XX, Chen QS, Shi WY, Wang L, Sun HD, Shen ZX, Chen Z, Chen SJ, Zhao WL.
    Exp Hematol; 2010 Mar 15; 38(3):191-201. PubMed ID: 20045442
    [Abstract] [Full Text] [Related]

  • 36. Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
    Zhang H, Li Z, Wang K.
    Oncol Rep; 2014 Apr 15; 31(4):1954-60. PubMed ID: 24549815
    [Abstract] [Full Text] [Related]

  • 37. Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification.
    Roy Choudhury S, Karmakar S, Banik NL, Ray SK.
    Invest New Drugs; 2010 Dec 15; 28(6):812-24. PubMed ID: 19777160
    [Abstract] [Full Text] [Related]

  • 38. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
    Mol Cancer Ther; 2016 Nov 15; 15(11):2553-2562. PubMed ID: 27496136
    [Abstract] [Full Text] [Related]

  • 39. Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway.
    Lin MT, Lin CL, Lin TY, Cheng CW, Yang SF, Lin CL, Wu CC, Hsieh YH, Tsai JP.
    Tumour Biol; 2016 May 15; 37(5):6987-96. PubMed ID: 26662956
    [Abstract] [Full Text] [Related]

  • 40. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
    Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW.
    Cancer Res; 2008 May 01; 68(9):3421-8. PubMed ID: 18451170
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.